LncRNA THOR acts as a retinoblastoma promoter through enhancing the combination of c-myc mRNA and IGF2BP1 protein
In conclusion, this study makes clear that lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells through up-regulating c-myc expression via enhancing its combination with TGF2BP1 protein. Overall, our study illustrates that lncRNA THOR/c-myc molecular cascade might be another potent target for retinoblastoma treatment.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Eye Cancers | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Osteosarcoma | Renal Cell Carcinoma | Retinoblastoma | Skin Cancer | Study